Reassuringly, the first clinical data with [177Lu]Lu-rhPSMA-10.1 from an intra-patient comparison with [177Lu]Lu-PSMA-I&T in patients with mCRPC show [177Lu]Lu-rhPSMA-10.1 to have a more favourable tumour-to-kidney therapeutic index than [177Lu]Lu-PSMA-I&T and is supportive of the preclinical observations [6]. Here, FOLH1 is linked to neoplasm.